Introduction

More than 2000 years ago, Hippocrates described a bidirectional relationship between depression and epilepsy.1 He wrote, “Melancholics ordinarily become epileptics, and epileptics, melancholics: what determines the preference is the direction the malady takes.”1 Many physicians have since noticed a connection between epilepsy and depression and anxiety. However, comorbid depression and anxiety disorders in people with epilepsy (PWE) have not been a focus in the field of epilepsy research and management for a long time, although many recent epidemiological studies have found a high prevalence of depression and anxiety in PWE.2-11 These studies found that 9–37% of PWE suffered from depression and 11–25% suffered from anxiety, which are higher proportions than found in those without epilepsy. These rates of depression and anxiety were close to that of drug-refractory epilepsy in a long-term population-based study.12 Despite major advances in the understanding and management of drug-refractory epilepsy, issues related to depression and anxiety in PWE remain underrecognized.

The prevalence of depression or anxiety is higher in drug-refractory epilepsy, and especially temporal-lobe epilepsy (TLE), than in the general population of PWE.2,4,7,13-17 Depression and anxiety are associated with suicide, suicidal ideation, and stigmatization in PWE.2,18-21 Recent studies have identified depression and anxiety as risk factors of drug-refractory epilepsy in newly diagnosed epileptic patients.22,23 These risk factors have also been associated with worse outcomes of epileptic surgery.24,25 In addition, depression and anxiety have been associated with increased adverse events in response to anti-
epileptic drugs (AEDs) in PWE. Ultimately, the psychiatric and clinical effects of depression and anxiety can impair the quality of life (QOL) of PWE. Therefore, early detection and management of depression and anxiety are critical for the management of PWE. Many valuable reports about depression and anxiety in PWE have been published. This review was designed to compile the information provided by these studies, organizing it according to epidemiology, pathogenic mechanism, clinical manifestation, impact, diagnosis, and treatment. This newly organized information may provide helpful guidelines for physicians who treat PWE.

Epidemiology of Depression and Anxiety in PWE

**Epidemiology of depression**

Epilepsy has bidirectional association with depression. In a matched longitudinal cohort study based on the UK General Practice Research Database, epilepsy was associated with an increased onset of depression before and after epilepsy diagnosis. This observation may suggest the presence of the common underlying pathophysiological mechanisms of epilepsy and depression. Depression is the most frequently occurring comorbid psychiatric disorder in epilepsy. Studies conducted in Canada, Italy, the UK, and the US have shown that the prevalence of depression was higher in PWE than in patients with other diseases or in the general population. Depression was also more frequent in PWE than in healthy controls in our study conducted in Korean tertiary-care hospitals: 27.8% of PWE and 8.8% of healthy controls were found to suffer from depression. A recent meta-analysis of population-based, original research found that the overall prevalence of active depression in PWE was 23.1%.

Table 1. Prevalence or frequency of depression by community-based and hospital-based studies in people with epilepsy

| Author, published year | Country | Sampling from | No. of sampled PWE | Age group | Detection | Duration | Prevalence or frequency |
|------------------------|---------|---------------|--------------------|-----------|-----------|----------|-------------------------|
| Jacoby et al., 1996     | UK      | Community     | 696                | ≥ 16 years old | HAD       | At the time of study | 9%                      |
| Ettinger et al., 2004   | US      | Community     | 775                | ≥ 18 years old | CES-D     | At the time of study | 36.5%                   |
| Gaitatzis et al., 2004  | UK      | Community     | 5834               | ≥ 16 years old | GPRD      | At the time of study | 18.2%                   |
| Kobau et al., 2006      | US      | Community     | 131                | ≥ 18 years old | Simple questionnaire* | During the past year | 32.6%                   |
| Tellez-Zenteno et al., 2007 | Canada | Community | 253 | ≥ 15 years old | WHM-CIDI | Lifetime | 17.4%                   |
| Kwon and Park, 2013     | Korea   | Hospital      | 576                | ≥ 18 years old | BDI       | At the time of study | 27.8%                   |

 BD: Beck Depression Inventory; CES-D: Center for Epidemiology Studies Depression Scale; GPRD: General Practice Research Database in England and Wales; HAD: Hospital Anxiety and Depression Scale; PWE: people with epilepsy; WHM-CIDI: World Mental Health Composite International Diagnostic Interview.

The prevalence of depression in TLE was the highest among all types of epilepsy according to studies conducted in Italy and the UK. Drug-refractory epilepsy was also associated with a higher prevalence of depression. In a study conducted in two primary care practices in the UK, the frequency of depression was 33% in patients with frequent seizures and 6% in patients in remission due to AEDs. Patients with uncontrolled epilepsy also exhibited higher rates of depression compared with those with poorly or well-controlled epilepsy in our own previous Korean survey. That study found that the rates of depression in people with uncontrolled epilepsy, those with poorly controlled epilepsy, those with well-controlled epilepsy, and healthy controls were 54.3%, 23.8%, 14.0%, and 8.8%, respectively.
Epidemiology of anxiety

The matched longitudinal cohort study based on the UK General Practice Research Database also found the bidirectional association between anxiety and epilepsy. Studies conducted in Canada, the UK, and the US have found that the prevalence of anxiety was higher in PWE than in people without epilepsy; specifically, it was 11–25% in PWE (Table 2) and 7–11% in people without epilepsy. Anxiety was more common in PWE than in healthy controls in our study conducted in Korean tertiary-care hospitals: the rates of anxiety were 15.3% in PWE and 3.2% in healthy controls.

As with the prevalence of depression, previous research has found that the prevalence of anxiety in PWE is affected by the epilepsy status. The reported rate of comorbid anxiety was higher in patients with drug-resistant epilepsy and patients with TLE than in all PWE, and higher in patients with TLE than in patients with primary generalized epilepsy or patients with other chronic diseases. According to studies performed in Canada and the UK, the prevalence of anxiety was 11–44% in people with drug-refractory epilepsy, while a study from Germany found that 19 of 97 consecutive outpatients with drug-resistant epilepsy (19.6%) suffered from anxiety. Furthermore, anxiety was reported in 19% of patients with TLE and in 24.7% of epileptic surgery candidates. The rate of anxiety in our Korean survey was higher in patients with uncontrolled epilepsy (31.1%) than in patients with poorly controlled epilepsy (14.3%), patients with well-controlled epilepsy (6.5%), and healthy controls (3.2%).

Comorbid depression and anxiety

Depression and anxiety are frequently comorbid, and in clinical practice it is difficult to evaluate them separately since both involve negative affective symptoms. Therefore, the close relationship between depression and anxiety may be caused not only by their frequent comorbidity but also by the negative affective symptoms that they share. The importance of the comorbid occurrence of primary depression and anxiety disorders has led to specifiers for anxiety being added to the diagnostic criteria for depressive disorders included in the fifth edition of the Statistical Manual of Mental Disorders (DSM-5).

Pathogenic Mechanisms of Depression and Anxiety in PWE

Pathogenic mechanisms of depression

Scientists have recently attempted to elucidate the pathophysiological mechanisms of depression and anxiety in people with epilepsy. These mechanisms include neurochemical changes, neurodevelopmental abnormalities, and neurostructural alterations. The neurochemical changes involve alterations in the levels of neurotransmitters such as serotonin, dopamine, and glutamate. Neurodevelopmental abnormalities may involve disruptions in brain development, while neurostructural alterations may involve changes in brain structure, such as alterations in gray matter volume.

Table 2. Prevalence or frequency of anxiety by community-based and hospital-based studies in people with epilepsy

| Author, published year | Country | Sampling from | No. of sampled PWE | Age group | Detection | Duration | Prevalence or frequency |
|------------------------|---------|--------------|--------------------|-----------|-----------|----------|-------------------------|
| Jacoby et al., 1996    | UK      | Community    | 696                | ≥16 years old | HAD      | At the time of study | 25%                     |
| Gaitatzis et al., 2004 | UK      | Community    | 5834               | ≥16 years old | GPRD     | At the time of study | 11.1%                   |
| Kobau et al., 2006     | US      | Community    | 131                | ≥18 years old | Simple questionnaire* | During the past year | 14.4%                   |
| Tellez-Zenteno et al., 2007 | Canada | Community    | 253                | ≥15 years old | WHM-CIDI | Lifetime | 22.8%                   |
| Kwon and Park, 2013    | Korea   | Hospital     | 568                | ≥18 years old | BAI      | At the time of study | 15.3%                   |

*2004 Healthstyle survey. BAI: Beck Anxiety Inventory, GPRD: General Practice Research Database in England and Wales, HAD: Hospital Anxiety and Depression Scale in PWE, PWE: people with epilepsy, WHM-CIDI: World Mental Health Composite International Diagnostic Interview.
ological relationship between depression and epilepsy,\textsuperscript{38} and many mechanisms for their bidirectional relationship have been suggested. Structural abnormalities, monoamine pathways, cerebral glucose metabolism, the hypothalamic-pituitary-adrenal (HPA) axis, and interleukin-1β all play a role in the common pathogenesis of these conditions. Studies that have examined depressed patients using high-resolution brain MRI have shown reductions in the volumes of various areas, including the frontal, temporal, and limbic regions. One study found that the volumes of the left and right hippocampi were significantly smaller in subjects with a history of major depression than in normal controls, and that the degree of volume reduction was correlated with the total duration of major depression.\textsuperscript{39} Given the strong association between depression and TLE found in other studies,\textsuperscript{17,47} findings of reductions in hippocampal volume suggest that depression and epilepsy reflect common structural abnormalities.\textsuperscript{40}

Monoamine activity, including that associated with serotonin, norepinephrine, and dopamine, was decreased in both depression and epilepsy.\textsuperscript{41} Among the monoamine pathways, the most plausible common pathogenic process for depression involves serotonin. The binding potential of the 5-hydroxytryptamine (serotonin)-1A (5-HT\textsubscript{1A}) receptor was reduced in various areas of the brains of depressed patients. Indeed, positron-emission tomography (PET) studies found that the 5-HT\textsubscript{1A} receptor binding potential was decreased in the frontal area, mesial temporal area, limbic cortex, and midbrain raphe of patients with depression.\textsuperscript{42} The expression level of the 5-HT\textsubscript{1A} receptor mRNA in the hippocampus was found to be reduced in a postmortem study of suicide victims with major depressive disorders.\textsuperscript{43} The role of serotonin in epilepsy was also confirmed by PET studies.\textsuperscript{44-46} Some PET studies found that the 5-HT\textsubscript{1A} receptor binding potential was reduced in various brain areas of patients with TLE, namely the temporal lobe, hippocampus, amygdala, anterior cingulate gyrus, insula, raphe nucleus, and thalamus. Areas with reduced 5-HT\textsubscript{1A} receptor binding potential were ipsilateral to the seizure focus, and occurred particularly in the seizure onset and propagation areas.\textsuperscript{47-49} An inverse correlation between the severity of depressive symptoms and the serotonergic effect has also been identified by PET studies of patients with TLE.\textsuperscript{50-52}

Glucose metabolism was reduced in the right dorsolateral prefrontal, bilateral insular, and superior temporal areas in a PET study involving subjects with unipolar depression.\textsuperscript{53} Glucose metabolism was increased in the left dorsolateral prefrontal cortex, right dorsal anterior cingulate cortex, and left inferior parietal cortex after 6 weeks of successful paroxetine therapy in another PET study involving male patients with major depression.\textsuperscript{54} Changes in cerebral glucose metabolism related to depression have also been investigated in PWE. Glucose hypometabolism in the bilateral inferior frontal\textsuperscript{55} and left temporal areas\textsuperscript{56} of patients with complex partial seizures was associated with comorbid depression. A history of preoperative depression and the development of postoperative depression were associated with glucose hypometabolism in the orbitofrontal cortex ipsilateral to the seizure focus in patients with TLE.\textsuperscript{57}

High serum corticosterone levels and an overactive HPA axis have been demonstrated in a rat model of comorbid depression and TLE. The extent of HPA axis overactivity was independent of recurrent seizures, but it was positively correlated with the severity of the depressed mood.\textsuperscript{58} The sequence associated with interleukin-1β signaling can be used to explain the pathogenesis of depression in TLE. Chronic epilepsy may activate interleukin-1β signaling, which may in turn induce HPA-axis overactivity and a consequent up-regulation of 5-HT\textsubscript{1A} autoreceptors in the midbrain raphe, resulting in reduced raphe-hippocampal serotonergic transmission. The accompanying serotonergic deficit may ultimately produce depressive symptoms in TLE.\textsuperscript{59}

**Pathogenic mechanisms of anxiety**

The amygdala is essential for the experience of fear, since it induces the associated autonomic and endocrinological responses. Furthermore, the output of the amygdala to the periaqueductal gray matter is responsible for the avoidance behavior associated with fear. The hippocampus is associated with re-experiencing fear, and the symptoms of anxiety disorders reflect the activation of the fear circuit involving these structures.\textsuperscript{59-61} Similar mechanisms underlie anxiety symptoms and epilepsy, in that both involve neurons discharging excitatory currents.\textsuperscript{62} Thus, the amygdala and hippocampus play crucial pathophysiological roles in both anxiety and epilepsy. The orbitofrontal cortex, insula, and cingulate gyrus are also essential in the central mediation of anxiety.\textsuperscript{56-58}

Inhibition of γ-aminobutyric acid (GABA) is an important factor in the pathogenesis of anxiety.\textsuperscript{59} The GABA\textsubscript{A} receptor subtype plays a role in controlling fear arousal. Drugs that stimulate GABA\textsubscript{A} receptors, such as benzodiazepines and barbiturates, may not only increase the threshold for seizure but also control anxiety by reducing neuronal excitability.\textsuperscript{59} Pentylenetetrazole acts as a proconvulsant by blocking GABA\textsubscript{A} receptors, and also induces anxiety symptoms.\textsuperscript{60} GABA\textsubscript{A} receptor binding was reduced in patients with panic disorder (PD) in a PET study; benzodiazepine site binding was reduced throughout the brain, with the largest reductions being observed in the right orbitofrontal cortex and right insula.\textsuperscript{61}

Selective serotonin-reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are effective in controlling anxiety symptoms. Since these drugs increase the concentration
of serotonin in synapses, the anxiolytic effects of these drugs suggest that serotonin plays a crucial role in anxiety disorders.62 One study found that the volume distribution of 5-HT1A receptor binding was reduced in the anterior cingulate gyrus, posterior cingulate gyrus, and raphe of patients with PD.58

Modulation of calcium channels is another important factor in the pathophysiology of anxiety.61 In animal models of anxiety, calcium-channel blockers can abolish anxiety symptoms.56-58 Of the various subtypes of calcium channel, the high-voltage calcium channels, and particularly the N and P/Q types, control the release of excitatory neurotransmitters in synapses. The α2δ subunit of calcium channels controls abnormal neuronal firing in anxiety and epilepsy.59

**Clinical Manifestations of Depression and Anxiety in PWE**

**Clinical manifestations of depression**
The symptoms of depressive disorders in PWE can be classified according to their temporal relationship with seizures. Peri-ictal depressive symptoms have a temporal relationship with seizures and can be subclassified as preictal, postictal, and ictal, whereas interictal depressive symptoms have no temporal relationship with seizure occurrence.

Dysphoric mood is the most common preictal symptom of depression, which occurs between several hours and several days before the seizure. The dysphoric mood may be more severe during the 24 hours immediately preceding a seizure.63 Postictal depressive symptoms do not always occur during the same day as the seizure, and may occur up to 5 days after it.64 One study found symptoms had a median duration of 24 hours, and the symptoms were poor frustration tolerance, loss of interest or pleasure, self-deprecation, feelings of guilt, crying bouts, and hopelessness of interest or pleasure, helplessness, irritability, feelings of worthlessness or excessive guilt, hopelessness, and suicidal ideation.66

The symptoms of depressive disorders experienced by PWE tended to involve a more chronic dysthymic history and markedly fewer symptomatic-free periods lasting from 1 day to several days. Therefore, this pattern of depression may be referred to as a dysthymic disorder associated with epilepsy.66 Another study found that the depressive disorders experienced by PWE tended to involve a more chronic dysthymic history and markedly fewer neurotic traits (i.e., somatization, anxiety, brooding, guilt, self-pity, hopelessness, and helplessness) than those of non-epileptics.72

**Clinical manifestations of anxiety**
Anxiety disorders in PWE can also be classified based on the temporal correlation between symptoms and seizure occur-
Preictal anxiety symptoms occur from several hours to several days before the seizure. The severity of the symptoms may increase as the time of the seizure approaches. Postictal fear occurs after a seizure and may persist for up to 7 days thereafter; such persistence is more frequent among drug-resistant patients with partial epilepsy. Anxiety symptoms almost identical to the symptoms of psychiatric disorders may occur as semilogic manifestations during the seizure. Nervousness, fear, anger, and irritability may occur as auras of seizures. Fear occurs as an aura among 10–15% of patients with partial seizures, and ictal fear is of sudden onset and brief duration. Seizures originating from the anteromedial area and cingulate gyrus may cause fear; for this reason ictal fear is closely associated with TLE. Anxiety symptoms may increase as the time of the seizure approaches. 

Among the symptoms of anxiety disorders experienced by PWE, the interictal symptoms are the easiest to detect because they have no temporal relationship with seizure occurrence. Interictal anxiety and panic attacks occur frequently in patients with partial seizures and are closely associated with a focus in the limbic area. These symptoms may also be relatively common in patients with primary generalized epilepsy. Anxiety symptoms vary in relation to current seizure frequency and psychosocial etiology were significant predictors of the development of anxiety symptoms. The most common anxiety symptom experienced by the PWE in that study was fear, but symptoms other than fear-namely anxious mood, tension, insomnia, impaired intellectual functioning, depressed mood, and cardiovascular and genitourinary symptoms-differed between patients with and without anxiety.

**Effects of Depression and Anxiety on PWE**

**Suicidality**

The lifetime prevalence of suicidal ideation was almost twice as high in PWE as in those without epilepsy in a Canadian community health survey. Furthermore, a population-based study found that the risk of committing suicide was three times higher among PWE than in controls, and was highest in PWE with comorbid psychiatric disorders; in particular, those with depression had a 32-fold higher risk of committing suicide. Suicidal ideation was more frequent among PWE with depression and/or anxiety symptoms than among PWE without these symptoms, and the major predictors of suicidal ideation in PWE in Korean hospital-based studies were found to be depression and other psychiatric symptoms rather than seizure-related variables.

**Stigmatization**

People with epilepsy experience stigmatization due to their epilepsy diagnosis. Nearly half of PWE in a European sample reported experiencing stigma, and high scores on the stigma scale were correlated with factors lowering the QOL such as worrying and having negative feelings about life. Perceived stigma was frequently associated with depression and anxiety in relation to current seizure frequency and psychosocial factors in a large community-based study in the UK. A US study found that the frequency of perceived stigma was greater in patients with incident epilepsy who had a lifetime history of depression or were in fair/poor health. A Korean hospital-based study also found that the frequency of perceived stigma was higher in PWE with depression or anxiety symptoms than in PWE without these symptoms.

**Adverse effects of AEDs**

Antiepileptic drug-related adverse effects are among the main reasons for discontinuation of these medicines, and AED toxicity can disrupt the daily activities of PWE. The adverse event profile of AEDs, measured using total scores on the Liverpool Adverse Event Profile (LAEP), was a major predictor of QOL in patients with well-controlled and drug-refractory epilepsy. Validation studies of the LAEP from Spain and Korea found that depression and anxiety symptoms were strongly correlated with LAEP total scores. A study of five outpatient epilepsy clinics in the US found that PWE with depression and anxiety were more likely to have worse LAEP total scores than were those without these disorders, even when these disorders were subsyndromal. Patients taking AEDs frequently make subjective cognitive complaints. Two hospital-based studies found that cognitive complaints were more strongly associated with depressive symptoms than with objective cognitive performance. Although various subjective complaints related to AEDs may reflect coexisting depression and anxiety symptoms, it is unclear whether objective adverse effects are also related to these symptoms. A recent Korean study measured the risk factors associated with lamotrigine-induced rash in newly diagnosed patients. That study applied a planned titration scheme and target doses and observed patients for 12 weeks. Patients with depressive symptoms were nine times more likely to develop a rash than
were those without depressive symptoms. Other risk factors were not identified in the analyses, and so these obtained results were explained in terms of a common immune-mediated pathogenesis associated with both depression and skin rash.

Responses to pharmacological and surgical treatments
Recent data revealed that one consequence of the bidirectional relationship between psychiatric disorders and epilepsy is a negative impact on responses to the pharmacological treatment of the seizure disorder. A retrospective study from the UK analyzed data from 780 patients with newly diagnosed epilepsy who had been followed over a 20-year period to investigate predictors of pharmacoresistance. Depression preceding the onset of the seizure disorder was associated with a greater-than-twofold higher risk of developing pharmacoresistant epilepsy.23 A prospective, hospital-based study conducted in Australia assessed the neuropsychiatric symptomatology of 138 newly diagnosed patients before they started AEDs.24 The seizure-free frequency after 12 months was lower for patients with higher pretreatment scores on the A-B Neuropsychological Assessment Scale (ABNAS). Another study found that ABNAS scores were correlated with anxiety and depression.25

A lifetime history of psychiatric disorders also appears to be related to poor postsurgical outcomes. A UK study that reviewed the medical records of 280 patients who underwent TLE surgery, found that patients with a preoperative psychiatric diagnosis were significantly less likely to remain seizure free (OR=0.53, 95% CI=0.28–0.98, p=0.04).24 A presurgical history of major depressive disorder (OR=5.23, p=0.003) was the most important risk factor associated with a nonfavorable seizure outcome after corticoamygdalohippocampectomy in another study investigating 115 patients with refractory TLE and mesial temporal sclerosis.25

QOL
The QOL tends to be worse in PWE than in the general population, not only because of seizures but also because of concurrent medical, psychiatric, and psychosocial problems.26 Specifically, several recent studies have shown that depression and anxiety symptoms were the major determinants of QOL. A study of patients with TLE in the US found that interictal anxiety and depressive symptoms accounted for more of the variance in QOL than did seizure frequency, severity, or chronicity.26 Among seizure-related, medical, AED-related, and psychiatric factors in a Korean hospital-based study, the strongest predictors of QOL were depression and anxiety, followed by seizure control.27 Indeed, the QOL was significantly better in patients with drug-refractory epilepsy without comorbid depression and anxiety symptoms than in patients with 1 year of seizure freedom but with such symptoms. Patients with coexisting depression and anxiety were more likely to have a poor QOL than were those with only one of these conditions.28 Thus, the authors recommended that clinicians should always consider the coexistence of depression and anxiety in each PWE and screen for both types of symptom simultaneously so as to prevent impairments in QOL.

The adverse events associated with AEDs can affect the extent to which depression affects QOL. The impact of depressive symptoms on QOL was 3.37 times higher than that of LAEP total scores in a Korean study conducted with patients with well-controlled epilepsy on monotherapy.29 However, the contribution of LAEP total scores to QOL was slightly greater than that of depressive symptoms in an Italian multicenter study conducted with patients with drug-refractory epilepsy.30 Thus, the burden of drug toxicity appears to be greater in those patients.

Diagnosis of Comorbid Depression and Anxiety in PWE
While identifying depression and anxiety is important for the ensuring the most appropriate management of PWE, these conditions have generally been neglected in outpatient neurology clinics due to the busyness of these settings and the lack of brief, self-administered screening tools specifically designed for PWE.31 Although comorbid depression and anxiety in PWE can be measured in structured psychiatric interviews, such as those employing the Structured Clinical Interview for DSM-IV Axis I Disorders32 and the Mini-International Neuropsychiatric Interview (MINI),33 these take a long time to complete. Therefore, rapid screening tests to identify depression or anxiety in busy clinical settings are currently being developed and validated.

Screening for depression
The most popular screening test for depression in PWE is the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), which is a brief, six-item questionnaire that was developed and validated in the US as a screening tool for depression in PWE.34 The six items are rated on a 4-point scale from 1 to 4, and so the total score ranges from 6 to 24, with a higher score indicating a higher level of depression. This instrument takes less than 3 minutes to complete, and a cutoff score of 15 is suggestive of a major depressive episode that would mandate referral to a psychiatrist for further evaluation. Seven recent studies aimed at validating the NDDI-E in different languages (i.e., Brazilian Portuguese, Italian, Spanish, Japanese, German, Korean, and Greek) also found that the
questionnaire was easy to administer and that its levels of reliability and validity were similar to those of the original version.96-102 The Korean version of the NDDI-E (K-NDDI-E) is presented in Table 3. Interestingly, the cutoff score for the validated instrument differed with its language: it was lowest (i.e., >11) for the K-NDDI-E, and highest (i.e., >16) for the Japanese NDDI-E. Therefore, further validation studies should be conducted in other countries in their respective native languages.

Clinicians who are too busy to use the NDDI-E to screen for depression can use the Patient Health Questionnaire-2 (PHQ-2) instead. A validation study of the NDDI-E and the PHQ-2 among PWE using the MINI in a primary-care setting found that the sensitivity and specificity were 80% and 100%, respectively, for the PHQ-2, and 100% and 85% for the NDDI-E, suggesting that the two instruments are comparable.103

Screening for anxiety

Unfortunately, there are currently no specific screening instruments to identify anxiety in PWE; however, the standardized clinical tools used to assess anxiety in psychiatric settings can be employed. The Hospital Anxiety and Depression Scale, a self-report scale measuring anxiety and depressive symptoms, was developed to investigate various dimensions of mood in patients with medical comorbidities.104 It includes anxiety (seven items) and depression (seven items) subscales, and the total score ranges from 0 to 21, with a higher score reflecting a worse psychiatric status. Subscale scores of >8 represent pathological levels of anxiety and depression.

The Generalized Anxiety Disorder-7 (GAD-7) is a recently introduced self-report questionnaire that addresses whether individuals have been bothered by anxiety-related problems during the previous 2 weeks. It includes questions that are scored on a 4-point scale from 0 to 3, with the total score ranging from 0 to 21 and a higher score indicating a higher level of anxiety.105 It requires less than 3 minutes to complete, and a score >9 supports a diagnosis of GAD. This instrument has been widely used by general practitioners106 and can be used to screen for GAD in PWE because it contains only seven items that address somatic symptoms that can be confused with the adverse effects of AEDs, the cognitive symptoms of the seizure disorder, or the underlying neurologic disorder associated with epilepsy.107 Recently, the validation of GAD-7 was performed in Korean PWE.108 A score >6 supported a diagnosis of GAD. The impact of adverse effects of AEDs on the GAD-7 was less than that on the K-NDDI-E.

Treatment

Depression and anxiety symptoms are gradually being recognized as important aspects of PWE. However, there is currently insufficient information about how to manage these conditions. In addition, neither patients nor physicians seem to be sufficiently concerned about depression and anxiety in PWE. Concerns that psychotropic drugs may aggravate seizures also lead some physicians to resist prescribing these drugs. To overcome these limitations, physicians must be provided with practical information about depression and anxiety in PWE. This information should make it easier for physicians to address the treatment of depression and anxiety in PWE.

Depression and anxiety are closely associated with each other, and they coexist in many PWE.14,109 Thus, amelioration of the symptoms of depression or anxiety is quite likely to reduce the symptoms of the other condition. One study found that 13% of patients in a general medical clinic exhibited symptoms of depression, and 67% of this group had moderate comorbid anxiety, the severity of which decreased in patients whose depression decreased after a follow-up period of 1 year.110

Guidelines for the treatment of depression and anxiety in PWE

The International League Against Epilepsy (ILAE) developed the international consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy.111 The purpose of these statements was to facilitate the appropriate management of various neuropsychiatric disorders in PWE. We extracted several elements from these statements for use as guidelines for the management of depression and anxiety in PWE.

| Table 3. The Korean version of Neurological Disorders Depression Inventory for Epilepsy |
|-----------------------------------------------|
| Please circle the number that best describes them over the past 2 weeks including the day of the assessment |
|                         | Always or often | Sometimes | Rarely | Never |
| Everything is a struggle | 4              | 3         | 2      | 1     |
| Nothing I do is right    | 4              | 3         | 2      | 1     |
| Feel guilty              | 4              | 3         | 2      | 1     |
| I’d be better off dead   | 4              | 3         | 2      | 1     |
| Frustrated               | 4              | 3         | 2      | 1     |
| Difficulty finding pleasure | 4          | 3         | 2      | 1     |
Such cases, citalopram can be substituted in PWE. It has therapeutic effects may develop over time in some patients. In however, a tolerance for sertraline that interferes with its therapeutical interactions with AEDs. In general, sertraline can be preferentially selected for the treatment of depression in PWE because it is safe to use in this population. However, a tolerance for sertraline that interferes with its therapeutic effects may develop over time in some patients. In such cases, citalopram can be substituted in PWE. It has more tolerable at high doses compared with other antidepressants. Among SSRIs, sertraline and citalopram have fewer pharmacokinetic interactions with AEDs. In general, sertraline can be preferentially selected for the treatment of depression in PWE because it is safe to use in this population. However, a tolerance for sertraline that interferes with its therapeutic effects may develop over time in some patients. In such cases, citalopram can be substituted in PWE. It has been reported that administering citalopram to PWE at 10–40 mg/day for 2 months or 20 mg/day for 4 months to treat depression did not increase the seizure frequency. Furthermore, the use of citalopram at 20 mg/day as an add-on to AEDs even reduced the seizure frequency in nondepressed patients with poorly controlled epilepsy. Venlafaxine is an SNRI and thus acts on both serotonergic and norepinephrine-reuptake neurotransmitters. This can be another effective option for the treatment of depression in PWE when SSRIs are not available. There are anecdotal reports of 75–225 mg/day of venlafaxine improving depressive symptoms without aggravating seizures in patients with partial epilepsy, which suggests that venlafaxine can be safely used in patients with partial epilepsy. The extended-release preparation of venlafaxine can be prescribed once per day; this preparation is therefore helpful for cognitively impaired PWE who have difficulty following complex medication regimens. When using SSRIs and SNRIs, it should be noted that the therapeutic effect may not manifest during the first 3–6 weeks after starting the drugs. In addition, SSRIs can sometimes cause restlessness and mild anxiety at the start of therapy. In those cases, a short course of a benzodiazepine may be helpful. When SSRIs and SNRIs are not available, TCAs are the drug of choice for depression in PWE. However, since TCAs have exhibit more side effects and are associated with cardiac toxicity in overdoses, it is recommended that plasma drug levels be monitored and interactions with other concomitant drugs be considered when TCAs are used. Two studies using the TCA doxepin provided evidence that antidepressants may improve seizure control in PWE.

**Table 4. Medication for depression in people with epilepsy**

| Drug family | Starting dose (mg/d) | Maximum dose (mg/d) |
|-------------|----------------------|---------------------|
| Sertraline (Zoloft®) SSRI | 25 | 200 |
| Citalopram (Celexa®) SSRI | 10 | 60 |
| Escitalopram (Lexapro®) SSRI | 5 | 30 |
| Paroxetine (Paxil®) SSRI | 10 | 60 |
| Fluoxetine (Prozac®) SSRI | 10 | 60 |
| Fluvoxamine (Luvox®) SSRI | 20 | 30 |
| Venlafaxine (Effexor®) SNRI | 37.5 | 300 |
| Duloxetine (Cymbalta®) SNRI | 30 | 120 |
| Amitriptyline (Biavil®) TCA | 25 | 300 |
| Imipramine (Tofranil®) TCA | 75 | 300 |
| Desipramine (Norpramin®) TCA | 100 | 300 |
| Doxepin (Silenor®) TCA | 25 | 300 |
| Nortriptyline (Pamelor®) TCA | 25 | 150 |

SNRI: selective serotonin and norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant.
A meta-analysis showed that treatment with antidepressants or certain AEDs along with behavioral treatments improved both depression and seizures in PWE with comorbid depression. Cognitive-behavioral therapy (CBT) alleviates depression in PWE, and a combination of psychotherapy and medication has been shown to be more effective than medication alone for the treatment of depression.

**Treatment of comorbid anxiety in PWE**

Antidepressants such as SSRIs and SNRIs have been shown to be effective against both anxiety and depression. CBT is also effective against anxiety and should be considered for the management of anxiety disorders in PWE. The appropriate treatment protocols differ slightly with the clinical pattern of the specific anxiety disorder experienced by PWE. Combined treatment with SSRIs and CBT is indicated in the acute phase of PD. In terms of long-term maintenance treatment, a combined approach or CBT alone may be appropriate. Both antidepressants and benzodiazepine can be used for the pharmacological management of PD. Antidepressants are at least equally effective as benzodiazepine for the management of anxiety associated with PD. Benzodiazepines are not superior to antidepressants for managing the depressive symptoms that may accompany PD.

Common treatment options for GAD also include CBT, SSRIs, SNRIs, benzodiazepines, antihistamines (e.g., hydroxyzine), and pregabalin. Pregabalin is an AED that can be the drug of first choice for both the long-term and short-term management of GAD in PWE. Pregabalin is also effective in ameliorating comorbid depression in GAD. A meta-analysis has revealed the efficacy of antidepressants such as imipramine, venlafaxine, and paroxetine for GAD.

In terms of SAD, SSRIs such as sertraline and paroxetine can be considered first-line treatment options. A Cochrane review found that various drugs, including SSRIs, monoamine oxidase inhibitors, reversible inhibitors of monoamine oxidase A (RIMAs), benzodiazepines, and gabapentin, were beneficial for the short-term management of SAD. SSRIs were more effective than RIMAs and decreased not only the symptom cluster of SAD but also comorbid depressive symptoms and associated disability. SSRIs are also considered first-line drugs for PTSD. Paroxetine and sertraline are the preferred SSRIs for reducing the severity of PTSD symptoms. CBT is a first-line treatment option for the management of mild-to-moderate OCD. Pharmacotherapy should be applied when severe symptoms remain even after CBT treatment or when the symptoms of OCD are severe. CBT is also always considered a first-line treatment for the management of OCD in PWE. As in the general population, drug treatments are needed when the therapeutic effect of CBT is insufficient in PWE with OCD. SSRIs, and particularly sertraline, are preferred for the pharmacological management of OCD.

**Proconvulsant effects of antidepressants**

Many physicians are concerned about antidepressants inducing seizures in nonepileptic patients. The proconvulsant effects of antidepressants may be enhanced by factors such as high serum concentrations and rapid dose escalations. Antidepressants should therefore be started at low doses and increased in small increments when applied to PWE. The individual characteristics of specific patients may also affect the likelihood of proconvulsant effects of antidepressants. It has been demonstrated that increased proconvulsant effects in PWE are associated with CNS pathology, electroencephalographic abnormalities, a personal or family history of epilepsy, and comorbid behavioral disturbances.

**Effects of AEDs on depression and anxiety**

Antiepileptic drugs are associated with several psychiatric problems due to the mechanisms of action underlying their antiepileptic activity. AEDs can be divided into two categories according to their psychotropic properties: 1) sedating or GABAergic drugs, and 2) activating or antiglutamatergic drugs. This classification is straightforward but can only partly explain the adverse psychiatric events of AEDs, which are also associated with indirect mechanisms due to their interaction with the underlying epileptic process. The positive and negative psychotropic properties of AEDs have been well summarized in a review article. Phenytoin, carbamazepine, valproate, lamotrigine, and oxcarbazepine are known to have a mood-stabilizing effect, and hence these drugs are recommended for the treatment of mood lability or bipolar disorder in PWE. Lamotrigine is also recommended for the treatment of depression.

Benzodiazepines, gabapentin, and pregabalin can be used to treat anxiety in PWE, whereas barbiturates, vigabatrin,
zonisamide, topiramate, tiagabine, and pregabalin may produce mood changes and are therefore not recommended for use in depressed patients. Lamotrigine, felbamate, and tiagabine may induce anxiety, irritability, and aggression, and so are not recommended for use in anxious patients. Levetiracetam is the most widely used AED in Korean PWE due to its high efficacy and low toxicity. However, it has been known to elicit irritability, aggression, depression, anxiety, and sometimes even suicidal ideation or attempts. Risk factors for developing adverse psychiatric problems with levetiracetam include a history of febrile convulsions, status epilepticus, or psychiatric problems. A recent study found an association between genetic variations in dopaminergic activity and the risk for adverse psychiatric effects during levetiracetam therapy.

Conclusions

Similar to the proportion of PWE with drug-refractory epilepsy, almost one-third of PWE suffer from depression and anxiety, but these conditions are often underrecognized and undertreated by clinicians. These psychiatric problems are likely to produce suicidal ideation or attempts, perceived stigmatization, adverse effects associated with AEDs, worse responses to pharmacological and surgical treatments of the seizure disorder, and a worse QOL. Therefore, clinicians should evaluate PWE for depression and anxiety using simple screening instruments that are able to rapidly detect symptoms of these disorders in busy clinical settings. Although a systematic review of the published literature identified methodological limitations in studies investigating treatments for depression and anxiety in PWE, it also provided evidence that both medication and psychotherapy alleviate these conditions. However, randomized controlled trials are needed to determine the most appropriate pharmacological and psychosocial treatments for depression and anxiety in PWE.

Conflicts of Interest

The authors have no financial conflicts of interest.

REFERENCES

1. Lewis AJ. Melancholia: a historical review. J Ment Health 1993;80:1-42.
2. Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia 1996;37:148-161.
3. Ettinger A, Reed M, Cramer J. Epilepsy Impact Project Group. Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology 2004;63:1008-1014.
4. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004;110:207-220.
5. Tellez-Zenteno JF, Patten SB, Jeté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48:2336-2344.
6. Gaitatzis A, Carroll K, Majeed A, W Sander J. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 2004;45:1613-1622.
7. Perini GI, Tosin C, Carraro C, Bernasconi G, Canavini MP, Canger R, et al. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 1996;61:601-605.
8. Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, et al. The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984;41:934-941.
9. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94.
10. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
11. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627.
12. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006;129(Pt 3):617-624.
13. O’Donoghue MF, Goodridge DM, Redhead K, Sander JW, Duncan JS. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract 1999;49:211-214.
14. Kwon OY, Park SP. Frequency of affectsive symptoms and their psychosocial impact in Korean people with epilepsy: a survey at two tertiary care hospitals. Epilepsy Behav 2013;26:51-56.
15. Manchanda R, Schaefer B, McLachlan RS, Blume WT, Wiebe S, Girvin JP, et al. Psychiatric disorders in candidates for surgery for epilepsy. J Neurol Neurosurg Psychiatry 1996;61:82-89.
16. Kobu R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its associations with self-reported depression and anxiety: results from the 2004 HealthStyles Survey. Epilepsia 2006;47:1915-1921.
17. Edel J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br J Psychiatry 1987;151:95-101.
18. Jones JE, Hermann BP, Barry JJ, Gilliam FG, Kanner AM, Meador KJ. Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy Behav Suppl 3:2006;S31-S38.
19. Lim HW, Song HS, Hwang YH, Lee HW, Suh CK, Park SP, et al. Predictors of suicidal ideation in people with epilepsy living in Korea. J Clin Neurol 2010;6:81-88.
20. Jacoby A. Felt versus enacted stigma: a concept revisited. Evidence from a study of people with epilepsy in remission. Soc Sci Med 1994;38:269-274.
21. Taylor J, Baker GA, Jacoby A. Levels of epilepsy stigma in an incident population and associated factors. Epilepsy Behav 2011;21:255-260.
22. Hithiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ, Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007;75:192-196.
23. Petrovski S, Snooke CE, Jones NC, Salzberg MR, Sheffield LJ, Huggins RM, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010;75:1015-1021.
24. Cheary RA, Thompson PJ, Foz Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia 2012;53:1705-1712.
25. de Araújo Filho GM, Gomes FL, Mazetto L, Marinho MM, Tavares IM, Caboclo LO, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure 2012;21:619-626.
Depression and Anxiety in People with Epilepsy

26. Kanner AM, Barry JJ, Gilliam F, Hermann B, Meador KJ. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia 2012;53(1):1104-1108.

27. Park SP. Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. Epilepsy Behav 2013;28:88-90.

28. Lisk M, Vahle L, Gross-Paju K, Haldre S. Subjective complaints compared to the results of neuropsychological assessment in patients with epilepsy: the influence of comorbid depression. Epilepsy Res 2009;84:194-200.

29. Marino SE, Meador KJ, Loring DW, Okun MS, Fernandez HH, Fesler AJ, et al. Subjective perception of cognition is related to mood and not performance. Epilepsy Behav 2009;14:459-464.

30. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012;72:184-191.

31. Fiest KM, Dykeman J, Patten SB, Wiebe S, Kaplan GG, Maxwell CJ, et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology 2013;80:590-599.

32. Brandt C, Schendienst M, Trentowska M, May TW, Pohlmann-Eden B, Tuschen-Caffier B, et al. Prevalence of anxiety disorders in patients with refractory focal epilepsy—a prospective clinic-based survey. Epilepsy Behav 2010;17:259-263.

33. Currie S, Heathfield KW, Herson RA, Scott DF. Clinical course and prognosis of temporal lobe epilepsy. A survey of 666 patients. Brain 1971;94:173-190.

34. Devinsky O, Barr WB, Vickrey BG, Berg AT, Bazil CW, Pacia SV, et al. Depression and epilepsy: how closely related are they? Neurology 2005;65:1744-1749.

35. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 1991;100:316-336.

36. Olino TM, Klein DN, Lewinsohn PM, Rohde P, Seeley JR. Longitudinal associations between depressive and anxiety disorders: a comparison of two trait models. Psychol Med 2008;38:353-363.

37. American Psychiatric Association. Bipolar and related disorders. In: American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA: American Psychiatric Association, 2013:123-188.

38. Kanner AM, Balabanov A. Depression and epilepsy: how closely related are they? Neurology 2002;58(5 Suppl 5):S27-S39.

39. Shelino YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996;93:3908-3913.

40. Deverts WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin1A receptor binding in depression. Biol Psychiatry 1999;46:1375-1387.

41. López JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor expression in temporal lobe epilepsy. Epilepsy Res 2002;51:153-163.

42. van den Heuvel PM, Sporns O, van den Heuvel OM, Bullmore ET. Resting state networks and disease. J Neurosci 2014;34(8):263-272.

43. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-272.

44. Rauch SL, Savage CR, Alpert NM, Miguel EC, Baer L, Breiter HC, et al. A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry 1995;52:20-28.

45. Vermetten E, Schmauld C, Southwick SM, Bremner JD. Positron tomographic emission study of olfactory induced emotional recall in veterans with and without combat-related posttraumatic stress disorder. Psychopharmacol Bull 2007;40:8-30.

46. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004;24:589-591.

47. Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009;11:1-9.

48. Jung ME, Lal H, Gatch MB. The discriminative stimulus effects of pentylentetrazol as a model of anxiety: recent developments. Neurosci Biobehav Rev 2005;29:429-439.

49. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-720.

50. Kanner AM, Ettinger AB. Anxiety disorders. In: Engel J Jr, Pedley TA, editors. Epilepsy: a Comprehensive Textbook. 2nd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2008:2139-2154.

51. Chugh Y, Saha N, Sankaranarayanan A, Sharma PL. Effect of peripher al administration of cinemaz/cinephram on the abstinence syndrome in diazepam-dependent rats. Psychopharmacology (Berlin) 1992;106:127-130.

52. Saad SF, Khayyal MT, Attia AS, Saad ES. Influence of certain calcium-channel blockers on some aspects of lorazepam-dependence in mice. J Pharm Pharmacol 1997;49:322-328.

53. Blommer P, Frommer GP. Mood change preceding epileptic seizures. J Neurol Ment Dis 1986;174:471-476.
66. Kanner AM, Blumenthal D. Affective disorders. In: Engel J Jr, Pedley TA, editors. Epilepsy: a Comprehensive Textbook. 2nd ed. Philadelphia: Wolters Kluver/Lippincott Williams & Wilkins, 2008:2123-2138.

67. Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 2004;62:708-713.

68. Daly D. Ictal affect. Am J Psychiatry 1958;115:97-108.

69. Weil AA. Depressive reactions associated with temporal lobe-uncinate seizure. J Nerv Ment Dis 1955;121:505-510.

70. Williams D. The structure of emotions reflected in epileptic experiences. Brain 1956;79:29-67.

71. Kanner AM, Kozak AM, Frey M. The use of Sertraline in Patients with Epilepsy: Is It Safe? Epilepsy Behav 2000;1:100-105.

72. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy. Significance and phenomenology. Arch Neurol 1986;43:766-770.

73. Hughes J, Devinsky O, Feldmann E, Bromfield E. Premonitory symptoms in epilepsy. Seizure 1993;2:201-203.

74. Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999;40 Suppl 10:S2-S20.

75. Devinsky O, Vazquez B. Behavioral changes associated with epilepsy. Neurol Clin 1993;11:127-149.

76. Gloor P, Olivier A, Quesney LF, Andermann F, Horowitz S. The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann Neurol 1982;12:129-144.

77. Devinsky O. A 48-year-old man with temporal lobe epilepsy and psychiatric illness. JAMA 2003;290:381-392.

78. Hermann BP, Chhabria S. Interictal psychopathology in patients with epilepsy. Epilepsy and risk of suicide: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005;17:172-179.

79. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33; quiz 34-57.

80. López-Gómez M, Espinola M, Ramirez-Bermudez J, Martinez-Juarez CA, et al. Determinants of health-related quality of life in pharmaco-resistant epilepsy: the forgotten psychiatric morbidity. Epilepsia 2009;50:1217-1226.

81. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Determinants of quality of life in people with epilepsy on monotherapy? Epilepsy Behav 2012;24:329-331.

82. Di Capua D, Garcia-Garcia ME, Reig-Ferrer A, Fuentes-Ferrer M, Toledano R, Gil-Nagel A, et al. Validation of the Spanish version of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Epilepsy Behav 2010;19:328-331.

83. Tadokoro Y, Oshima T, Fukuchi T, Kanner AM, Kanemoto K. Screening for major depressive episodes in Japanese patients with epilepsy: validation and translation of the Japanese version of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). Epilepsy Behav 2012:24:18-22.

84. Park JM, Seo JG, Kim HW, Park SP. Reliability and validity of the Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E). Epilepsy Behav 2012:25:485-488.

85. Ko PW, Hwang J, Lim HW, Park SP. Reliability and validity of the Korean version of the Neurological Disorders Depression Inventory for Epilepsy (K-NDDI-E). Epilepsy Behav 2012:25:539-542.

86. Zis P, Yliantti P, Siatouni A, Tavernarakis A, Gatzonis S. Validation of the hospital anxiety and depression scale: a multinational study in people with epilepsy. Seizure 2005;14:120-124.

87. Carreño M, Donaire A, Falip M, Maestro I, Fernández S, Nagel AG, et al. Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav 2009;15:154-159.

88. Kwon OY, Park SP. What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy? Epilepsy Behav 2011;20:528-532.

89. Luoni C, Bisulli F, Canavini MP, De Sarro G, Fattore C, Galmieri CA, et al. Determinants of health-related quality of life in pharmaco-resistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 2011;52:2181-2191.

90. Carreño M, Donaire A, Falip M, Maestro I, Fernández S, Nagel AG, et al. Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav 2009;15:154-159.

91. Park SP, Song HS, Hwang YH, Lee HW, Suh CK, Kwon SH. Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy. Epilepsy Behav 2010;18:455-459.

92. Friedman DE, Kung DH, Lauwattana S, Kass JS, Hraochov RA, Levin HS. Identifying depression in epilepsy in a busy clinical setting is enhanced with systematic screening. Seizure 2009;18:429-433.

93. Jones JE, Hermann BP, Barry JJ, Gilliam F, Kanner AM, Meador KJ. Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005;17:172-179.

94. Baker GA, Brooks J, Buck D, Jacoby A. The stigma of epilepsy: a European perspective. Epilepsia 2000;41:98-104.

95. Leaffer EB, Jacoby A, Benn E, Hauser WA, Shi T, Dayan P, et al. Assessing generalized anxiety disorder in patients with epilepsy. Am J Psychiatry 2003:160:18-24; quiz 34-57.

96. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.

97. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-1097.

98. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-325.

99. Kanner AM. Anxiety disorders in epilepsy: the forgotten psychiatric comorbidity. Epilepsy Curr 2011;11:90-91.

100. Seo JG, Cho YW, Lee SJ, Lee JJ, Kim JE, Moon HJ, et al. Validation of the Generalized Anxiety Disorder-7 in people with epilepsy: A MEPSY study. Epilepsy Behav 2012:33:59-63.

101. Kanner AM. Psychiatric issues in epilepsy: the complex relation of
Depression and Anxiety in People with Epilepsy

mood, anxiety disorders, and epilepsy. *Epilepsy Behav* 2009;15:83-87.

110. Zung WW, Magruder-Habib K, Velez R, Alling W. The comorbidity of anxiety and depression in general medical patients: a longitudinal study. *J Clin Psychiatry* 1990;51 Suppl:77-80: discussion 81.

111. Kerr MP, Mensah S, Besag F, de Toффil B, Ettinger A, Kanemoto K, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. *Epilepsia* 2011;52:2133-2138.

112. Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. *Epilepsy* 2013;54 Suppl 1: S1-S29.

113. Barry JJ, Ettinger AB, Friel P, Gilliam FG, Harden CL, Hermann B, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. *Epilepsy Behav* 2008;13 Suppl 1: S1-S29.

114. Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. *Seizure* 2003;12:316-318.

115. Ojemann LM, Baugh-Bookman C, Dudley DL. Effect of doxepin on seizure frequency in depressed epileptic patients. *Neurology* 1983;33: 646-648.

116. Ojemann LM, Baugh-Bookman C, Dudley DL. Effect of psychotropic medications on seizure control in patients with epilepsy. *Neurology* 1987;37:1525-1527.

117. Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and depression: a systematic literature review. *Epilepsy Behav* 2013;28:36-40.

118. Lee JJ, Song HS, Hwang YH, Lee HW, Suh CK, Park SP. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. *J Clin Neuro 2011;7:128-136.

119. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. *Neurology* 2003;61:704-706.

120. Kanner AM. Psychiatric comorbidity in patients with developmental disorders and epilepsy: a practical approach to its diagnosis and treatment. *Epilepsy Behav* 2002;3:7-13.

121. Curran S, de Pauw K. Selecting an antidepressant for use in a patient with epilepsy. *Safety considerations*. *Drug Saf* 1998;18:125-133.

122. Spiller HA, Ramoska EA, Krenzelok EP, Sheen SR, Borys DJ, Villalobos D, et al. Bupropion overdose: a 3-year multi-center retrospective analysis. *Am J Emerg Med* 1994;12:43-45.

123. Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. *Gen Hosp Psychiatry* 1987;9:135-141.

124. Harris CR, Gualtieri J, Stark G. Fatal bupropion overdose. *J Toxicol Clin Toxicol* 1997;35:321-324.

125. Blumer D. Psychiatric aspects of intractable epilepsy. *Adv Exp Med Biol* 2002;497:133-147.

126. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. *Neurology* 1999;53(5 Suppl 5):S35-S367.

127. Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. *Epilepsy Behav* 2013;26:440-449.

128. Lee JJ, Song HS, Hwang YH, Lee HW, Sab CK, Park SP. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. *J Clin Neuro 2011;7:128-136.

129. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. *Neurology* 2003;61:704-706.

130. Helmsdæther C, Mihov Y, Toliat MR, Thiele H, Nürenberg P, Schoch S, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. *Epilepsia* 2013;54:36-44.